CDKN2A and cancer: Consistent with prior studies investigating metabolic reprogramming in cancer, we observed significant upregulation of key cuproptosis-related genes, including FDX1, GLS, and CDKN2A, in tumor tissues compared to normal counterparts [32, 33].